Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Enanta Pharma Q3 2024 Adj EPS $(1.07) Beats $(1.45) Estimate, Sales $18.00M Beat $17.18M Estimate

Author: Benzinga Newsdesk | August 05, 2024 04:18pm
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.45) by 26.21 percent. The company reported quarterly sales of $18.00 million which beat the analyst consensus estimate of $17.18 million by 4.78 percent. This is a 4.72 percent decrease over sales of $18.89 million the same period last year.

Posted In: ENTA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist